[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
 Darp101 [@DarpResearch](/creator/twitter/DarpResearch) on x XXX followers
Created: 2025-07-17 13:06:36 UTC
NervGen $NGENF Announces Leadership Transition to Support Strategic Growth and Expansion u/newsfile/nervgen-announces-leadership-transition-to-support
I am not surprised. I have recently talked with Mike, a likeable fellow. The presentation of the wonderful results was way too cautious, as I and many others have voiced. I guessed that the board may have felt the same way. Hence my big increase in trying to communicate to the public both what this means for the patients and for the investors in NervGen, to compensate for that hypercaution. And my lack of surprise about today's news.
I do think this is a positive. As mentioned before, there should have been X or so carefully crafted PRs ready weeks before results came out that would fit the various outcomes in the trial, then they could put out the appropriate one. Instead of that, on the fly, a hypercautious PR came out. It took me X weeks to figure out just how good these results were.
Look forward to a move away from the hyper caution, as this is potentially the most beneficial medical news of 2025, from the perspective of 2030 or 2035. Cheers
President and Chief Executive Officer Mike Kelly has stepped down as a director and officer of the Company and Dr. Adam Rogers, Chair of the Board and representative of NervGen's largest shareholder, has been appointed Interim CEO.
XXX engagements
**Related Topics**
[$ngenf](/topic/$ngenf)
[Post Link](https://x.com/DarpResearch/status/1945832509998284845)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Darp101 @DarpResearch on x XXX followers
Created: 2025-07-17 13:06:36 UTC
NervGen $NGENF Announces Leadership Transition to Support Strategic Growth and Expansion u/newsfile/nervgen-announces-leadership-transition-to-support I am not surprised. I have recently talked with Mike, a likeable fellow. The presentation of the wonderful results was way too cautious, as I and many others have voiced. I guessed that the board may have felt the same way. Hence my big increase in trying to communicate to the public both what this means for the patients and for the investors in NervGen, to compensate for that hypercaution. And my lack of surprise about today's news. I do think this is a positive. As mentioned before, there should have been X or so carefully crafted PRs ready weeks before results came out that would fit the various outcomes in the trial, then they could put out the appropriate one. Instead of that, on the fly, a hypercautious PR came out. It took me X weeks to figure out just how good these results were.
Look forward to a move away from the hyper caution, as this is potentially the most beneficial medical news of 2025, from the perspective of 2030 or 2035. Cheers
President and Chief Executive Officer Mike Kelly has stepped down as a director and officer of the Company and Dr. Adam Rogers, Chair of the Board and representative of NervGen's largest shareholder, has been appointed Interim CEO.
XXX engagements
Related Topics $ngenf